Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased RUNX3 expression mediates tumor-promoting ability of human breast cancer-associated fibroblasts.
Koyama Y, Okazaki H, Shi Y, Mezawa Y, Wang Z, Sakimoto M, Ishizuka A, Ito Y, Koyama T, Daigo Y, Takano A, Miyagi Y, Yokose T, Yamashita T, Sugahara K, Hino O, Yang L, Maruyama R, Katakura A, Yasukawa T, Orimo A. Koyama Y, et al. Among authors: ishizuka a. Cancer Med. 2023 Sep;12(17):18062-18077. doi: 10.1002/cam4.6421. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37641472 Free PMC article.
Thioxothiazolidin derivative, 4-OST, inhibits melanogenesis by enhancing the specific recruitment of tyrosinase-containing vesicles to lysosome.
Isogawa K, Asano M, Hayazaki M, Koga K, Watanabe M, Suzuki K, Kobayashi T, Kawaguchi K, Ishizuka A, Kato S, Ito H, Hamamoto A, Koyama H, Furuta K, Takemori H. Isogawa K, et al. Among authors: ishizuka a. J Cell Biochem. 2021 Jun;122(6):667-678. doi: 10.1002/jcb.29895. Epub 2021 Jan 22. J Cell Biochem. 2021. PMID: 33480093
Combination immunotherapy with vaccine and oncolytic HSV virotherapy is time dependent.
Totsch SK, Ishizuka AS, Kang KD, Gary SE, Rocco A, Fan AE, Zhou L, Valdes PA, Lee S, Li J, Peruzzotti-Jametti L, Blitz S, Garliss CM, Johnston JM, Markert JM, Lynn GM, Bernstock JD, Friedman GK. Totsch SK, et al. Among authors: ishizuka as. Mol Cancer Ther. 2024 May 6. doi: 10.1158/1535-7163.MCT-23-0873. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38710101
Structural basis for self-discrimination by neoantigen-specific TCRs.
Finnigan JP, Newman JH, Patskovsky Y, Patskovska L, Ishizuka AS, Lynn GM, Seder RA, Krogsgaard M, Bhardwaj N. Finnigan JP, et al. Among authors: ishizuka as. Nat Commun. 2024 Mar 8;15(1):2140. doi: 10.1038/s41467-024-46367-9. Nat Commun. 2024. PMID: 38459027 Free PMC article.
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.
Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM, Tobin KKS, Lynn GM, Khalilnezhad S, Ginhoux F, Van den Eynde BJ, Leung CSK, Ishizuka AS, Seder RA. Ramirez-Valdez RA, et al. Among authors: ishizuka as. Cell Rep. 2023 Jun 27;42(6):112599. doi: 10.1016/j.celrep.2023.112599. Epub 2023 Jun 7. Cell Rep. 2023. PMID: 37279110 Free PMC article.
Structural Basis for Self-Discrimination by Neoantigen-Specific TCRs.
Finnigan JP, Newman JH, Patskovsky Y, Patskovska L, Ishizuka AS, Lynn GM, Seder RA, Krogsgaard M, Bhardwaj N. Finnigan JP, et al. Among authors: ishizuka as. Res Sq [Preprint]. 2023 Jan 31:rs.3.rs-2531184. doi: 10.21203/rs.3.rs-2531184/v1. Res Sq. 2023. PMID: 36778273 Free PMC article. Updated. Preprint.
Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment.
Baharom F, Ramirez-Valdez RA, Khalilnezhad A, Khalilnezhad S, Dillon M, Hermans D, Fussell S, Tobin KKS, Dutertre CA, Lynn GM, Müller S, Ginhoux F, Ishizuka AS, Seder RA. Baharom F, et al. Among authors: ishizuka as. Cell. 2022 Nov 10;185(23):4317-4332.e15. doi: 10.1016/j.cell.2022.10.006. Epub 2022 Oct 26. Cell. 2022. PMID: 36302380 Free PMC article.
91 results